AS1411 is
a DNA aptamer that is in phase II clinical trials for relapsed or refractory
acute myeloid leukemia and for
renal cell carcinoma.
AS1411 binds to
nucleolin, a
protein that is overexpressed in the cytoplasm and on the plasma membrane of some
tumor cells compared with normal cells. Studies were performed to determine whether cell surface
nucleolin is a receptor for
AS1411 in the
acute myeloid leukemia cell line MV4-11. Biotinylation of MV4-11
cell surface proteins followed by immunoblotting of the biotinylated
proteins showed that full-length (106 kDa) and truncated forms of
nucleolin were present on the cell surface. In contrast, K-562 cells, which are 4-fold less sensitive than MV4-11 cells to
AS1411, showed no full-length
nucleolin and lesser amounts of the truncated forms of
nucleolin on the cell surface. Incubation of MV4-11 cells with [(32)P]
AS1411 and immunoprecipitation of the plasma membrane fraction with anti-
nucleolin antibody demonstrated the presence of [(32)P]
AS1411-
nucleolin complexes. Anti-
nucleolin antibody inhibited binding of
fluorescein isothiocyanate (FITC)-AS1411 to plasma membrane
nucleolin 56 +/- 10% SE (P < 0.01) compared with cells incubated with FITC-AS1411 only. Cellular uptake of [(32)P]
AS1411 into MV4-11 cells was blocked by a 20-fold excess of unlabeled
AS1411 but not by a 20-fold excess of the biologically inactive
oligonucleotide CRO-26. Uptake was approximately 3-fold faster into MV4-11 cells than into K-562 cells. Partial knockdown of plasma membrane and cytosolic
nucleolin in MCF-7 cells resulted in a 3-fold decrease in
AS1411 uptake. These results provide evidence that plasma membrane
nucleolin is a functional receptor for
AS1411 in MV4-11 cells.